Bruna da Silva Soley1, Leonardo Martins Silva2, Daniel Augusto Gasparin Bueno Mendes3, André Báfica3, João Bosco Pesquero2, Michael Bader4,5,6,7, Deborah A Witherden8, Wendy L Havran8, João B Calixto9, Michel Fleith Otuki1, Daniela Almeida Cabrini1. 1. Department of Pharmacology, Federal University of Parana, Curitiba, Brazil. 2. Department of Biophysics, Federal University of São Paulo, São Paulo, Brazil. 3. Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina, Florianópolis, Brazil. 4. Max Delbrück Center for Molecular Medicine (MDC), Berlin, Germany. 5. Institute for Biology, University of Lübeck, Germany. 6. Charité University Medicine, Berlin, Germany. 7. German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany. 8. Immunology and Microbiology, Scripps Research Institute, La Jolla, California, USA. 9. Center of Innovation and Preclinical Studies (CIENP), Florianópolis, Brazil.
Abstract
BACKGROUND AND PURPOSE: The entire kallikrein-kinin system is present in the skin, and it is thought to exert a relevant role in cutaneous diseases, including psoriasis. The present study was designed to evaluate the relevance of kinin receptors in the development and progression of a model of psoriasis in mice. EXPERIMENTAL APPROACH: The effects of kinin B1 and B2 receptor knockout and of kinin receptor antagonists (SSR240612C or FR173657) were assessed in a model of psoriasis induced by imiquimod in C57BL/6 mice. Severity of psoriasis was assessed by histological and immunohistochemical assays of skin, along with objective scores based on the clinical psoriasis area and severity index. KEY RESULTS: Both kinin receptors were up-regulated following 6 days of imiquimod treatment. Kinin B1 and B2 receptor deficiency and the use of selective antagonists show morphological and histological improvement of the psoriasis hallmarks. This protective effect was associated with a decrease in undifferentiated and proliferating keratinocytes, decreased cellularity (neutrophils, macrophages, and CD4+ T lymphocytes), reduced γδ T cells, and lower accumulation of IL-17. The lack of B2 receptors resulted in reduced CD8+ T cells in the psoriatic skin. Relevantly, blocking kinin receptors reflected the improvement of psoriasis disease in the well-being behaviour of the mice. CONCLUSIONS AND IMPLICATIONS: Kinins exerted critical roles in imiquimod-induced psoriasis. Both B1 and B2 kinin receptors exacerbated the disease, influencing keratinocyte proliferation and immunopathology. Antagonists of one or even both kinin receptors might constitute a new strategy for the clinical treatment of psoriasis.
BACKGROUND AND PURPOSE: The entire kallikrein-kinin system is present in the skin, and it is thought to exert a relevant role in cutaneous diseases, including psoriasis. The present study was designed to evaluate the relevance of kinin receptors in the development and progression of a model of psoriasis in mice. EXPERIMENTAL APPROACH: The effects of kinin B1 and B2 receptor knockout and of kinin receptor antagonists (SSR240612C or FR173657) were assessed in a model of psoriasis induced by imiquimod in C57BL/6 mice. Severity of psoriasis was assessed by histological and immunohistochemical assays of skin, along with objective scores based on the clinical psoriasis area and severity index. KEY RESULTS: Both kinin receptors were up-regulated following 6 days of imiquimod treatment. Kinin B1 and B2 receptor deficiency and the use of selective antagonists show morphological and histological improvement of the psoriasis hallmarks. This protective effect was associated with a decrease in undifferentiated and proliferating keratinocytes, decreased cellularity (neutrophils, macrophages, and CD4+ T lymphocytes), reduced γδ T cells, and lower accumulation of IL-17. The lack of B2 receptors resulted in reduced CD8+ T cells in the psoriatic skin. Relevantly, blocking kinin receptors reflected the improvement of psoriasis disease in the well-being behaviour of the mice. CONCLUSIONS AND IMPLICATIONS: Kinins exerted critical roles in imiquimod-induced psoriasis. Both B1 and B2 kinin receptors exacerbated the disease, influencing keratinocyte proliferation and immunopathology. Antagonists of one or even both kinin receptors might constitute a new strategy for the clinical treatment of psoriasis.
Authors: Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman Journal: J Cereb Blood Flow Metab Date: 2011-01-05 Impact factor: 6.200
Authors: Stephen P H Alexander; Arthur Christopoulos; Anthony P Davenport; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2019-12 Impact factor: 8.739
Authors: Carola E Matus; Pamela Ehrenfeld; Francisca Pavicic; Carlos B González; Miguel Concha; Kanti D Bhoola; Rafael A Burgos; Carlos D Figueroa Journal: Exp Dermatol Date: 2016-06-15 Impact factor: 3.960
Authors: J A Borkowski; R W Ransom; G R Seabrook; M Trumbauer; H Chen; R G Hill; C D Strader; J F Hess Journal: J Biol Chem Date: 1995-06-09 Impact factor: 5.157
Authors: Bruna da Silva Soley; Leonardo Martins Silva; Daniel Augusto Gasparin Bueno Mendes; André Báfica; João Bosco Pesquero; Michael Bader; Deborah A Witherden; Wendy L Havran; João B Calixto; Michel Fleith Otuki; Daniela Almeida Cabrini Journal: Br J Pharmacol Date: 2020-05-30 Impact factor: 8.739